Actively Recruiting
PIC1 Injection Therapy for Relapsed/Refractory B-NHL
Led by Chongqing Precision Biotech Co., Ltd · Updated on 2026-03-06
18
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an investigator-initiated trial aimed at assessing the safety and efficacy of PIC1 injection in the treatment of relapsed/refractory B-cell Non-Hodgkin Lymphoma.
CONDITIONS
Official Title
PIC1 Injection Therapy for Relapsed/Refractory B-NHL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient or legally authorized representative has voluntarily agreed to participate and signed informed consent
- Age between 18 and 75 years, any gender
- Histologically or cytologically confirmed B-cell Non-Hodgkin Lymphoma according to WHO 2017 classification, including specified subtypes
- Received prior therapy including anti-CD20 monoclonal antibody and anthracycline unless contraindicated or intolerant
- Meet definition of relapsed or refractory disease as specified
- Confirmed CD19 positivity by immunohistochemistry or flow cytometry
- ECOG performance status of 0 or 1
- Estimated life expectancy of at least 12 weeks
- At least one measurable lesion per 2014 Lugano Criteria with specified size
- Adequate major organ function including cardiac, renal, hepatic, oxygenation, and hematologic parameters
- Women of childbearing potential must have negative pregnancy test and agree to use effective contraception until one year after infusion
You will not qualify if you...
- Prior CAR-T therapy or any gene-modified cell therapy before screening
- Received anti-tumor therapies or radiation within specified timeframes before infusion, except allowed treatments
- Cardiac conditions including NYHA Class III or IV heart failure, recent myocardial infarction or bypass surgery, significant arrhythmias, or severe non-ischemic cardiomyopathy
- Active or uncontrolled infection requiring systemic treatment within one week before screening
- Grade 2-4 acute graft-versus-host disease or moderate-to-severe chronic graft-versus-host disease within four weeks before screening
- Recent cerebrovascular accident, seizure, deep vein thrombosis, or arterial embolism within six months before screening
- History of other malignancies except certain treated cancers with no active disease
- Received live attenuated vaccine within four weeks before screening
- Any condition deemed unsuitable for participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
J
Jia Wei
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here